Plain-English translation of NCT06011954 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a tracking study for adults in South Korea with advanced bladder cancer (urothelial cancer) who are being treated with PADCEV Injection. Researchers will follow your medical care over about one year to see how well the medication works and to record any medical problems you experience during treatment.
Now that this medication is available to patients, doctors want to understand how it performs in real-world clinical practice and keep a careful record of its safety and effectiveness in the South Korean population.
You likely qualify if…
You likely don't qualify if…
Once your doctor prescribes the medication, you will continue your normal cancer treatment at your clinic. Researchers will review your medical records for up to 48 weeks (about one year) from your first dose to track how you're responding and note any side effects. If you stop the medication early, they will continue reviewing your records for 30 days after your last dose or when you start a different cancer treatment.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
South Korea